---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-035098"
form_type: "8-K"
ticker: "OCEA"
cik: "0001869974"
company_name: "Ocean Biomedical, Inc."
filed_at: "2023-10-03T23:59:59+00:00"
generated_at: "2026-06-10T05:40:36.003417+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Ocean Biomedical amends VWAP trigger and reset price in side letter with Polar

## Summary
- Side letter dated October 2, 2023 amends definitions for Polar under Feb 2023 Novation Agreement.
- Seller VWAP Trigger Event occurs if VWAP below $2.50 for 20 of 30 consecutive trading days.
- Reset Price set at $8.00, subject to reduction via Dilutive Offering Reset.
- Amendment applies only to Polar's 2,666,667 shares under the Forward Purchase Agreement.
- All other terms of Novation and Forward Purchase Agreements remain unchanged.

## SEC filing metadata
- accession: 0001493152-23-035098
- form_type: 8-K
- ticker: OCEA
- cik: 0001869974
- company_name: Ocean Biomedical, Inc.
- filed_at: 2023-10-03T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1869974/000149315223035098/0001493152-23-035098-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1869974/000149315223035098/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-035098
- JSON: https://secwatch.observer/filing/0001493152-23-035098.json
- Plain text: https://secwatch.observer/filing/0001493152-23-035098.txt

## Key facts
- Material Agreements
  Ocean Biomedical, Inc. amended Side Letter with Polar Multi-Strategy Master Fund (effective 2023-10-02).
  - Action: amendment
  - Counterparty: Polar Multi-Strategy Master Fund
  - Effective: 2023-10-02
  source text: On October 2, 2023, Ocean Biomedical, Inc. (the “Company”), entered into a Side Letter Agreement (the “Side Letter”) with Polar Multi-Strategy Master Fund (“Polar”). The Side Letter amends certain terms of the Assignment and Novation Agreement (the “Polar Agreement”), dated February 13, 2023, between the Company, Polar, Ocean Biomedical Holdings, Inc., and Vellar Opportunity Fund SPV – Series 3.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1869974/000149315223035098/0001493152-23-035098-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.